Trial reportRespirology (Carlton, Vic.)2025
Risk Model for Predicting Survival Outcomes Using Functional Exercise and Patient-Reported Outcomes in Fibrotic Interstitial Lung Disease: A Prospective Observational Study.
Trial report in Respirology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06476470 (A Prospective Multi-center Registry for Fibrotic Lung Disease, Focusing on Clinical Phenotype, Physical Parameters, Image Analysis, and Precision Medicine in Taiwan), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Multi-center Registry for Fibrotic Lung Disease, Focusing on Clinical Phenotype, Physical Parameters, Image Analysis, and Precision Medicine in Taiwan
Who cites it
3 citing papers in PubMed.
- Risk Model for Predicting Survival Outcomes Using Functional Exercise and Patient-Reported Outcomes in Fibrotic Interstitial Lung Disease: A Prospective Observational Study.Respirology (Carlton, Vic.) · 2025Trial
- Integrated imaging-informed and machine learning-based prognostic models for risk stratification in connective tissue disease-associated interstitial lung disease: a multicenter study.Clinical rheumatology · 2026Article
- Three-minute walk test as a practical screening tool for detecting exertional hypoxemia in fibrotic interstitial lung disease: a real-world cohort study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectiveFibrotic interstitial lung disease (F-ILD) has high mortality, necessitating multidimensional staging to assess severity, predict prognosis, and guide treatment. However, the gender-age-physiology (GAP) index lacks patient-reported outcome measures (PROMs) and exercise test parameters, and traditional methods may miss complex variable interactions. The study aimed to develop a risk model of mortality in F-ILD using routine PROMs and exercise test parameters, and to compare the predictive performance with GAP staging system.
methodsBetween December 2018 and December 2022, 246 patients from the ILD Prospective Registry with at least 1 year of follow-up (excluding death) were enrolled. Baseline assessments included GAP, 1MSTS, 6MWD, mMRC, SGRQ, and SF36. A tree-based risk model was developed and validated with a 2:1 split. Kaplan-Meier curves and Cox regression were used to estimate survival and hazard ratios, with statistical significance set at p < 0.05.
resultsThe very-high-risk group (SGRQ > 34.5, 1MSTS < 21) had a significantly higher hazard ratio (HR = 5.13; 95% CI: 2.54-10.35) compared to the non-very-high-risk group. Their 1-, 2-, and 5-year mortality rates were 28.87%, 47.18%, and 82.42%, respectively, similar to GAP stage III but with narrower confidence intervals.
conclusionThis study developed a prognostic model for F-ILD combining PROMs and functional exercise data. The model, which includes the SGRQ, 6MWD, and 1MSTS, outperforms GAP staging, offering benefits like reduced patient fatigue and improved monitoring. Multicenter studies are needed to validate these findings.
trial registrationThe study was registered on ClinicalTrials.gov (NCT06476470).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.